Savara (NASDAQ:SVRA – Get Free Report) and Champions Oncology (NASDAQ:CSBR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Valuation and Earnings
This table compares Savara and Champions Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Savara | N/A | N/A | -$118.84 million | ($0.56) | -8.96 |
| Champions Oncology | $56.94 million | 1.47 | $4.70 million | ($0.16) | -37.56 |
Analyst Ratings
This is a summary of current ratings and target prices for Savara and Champions Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Savara | 1 | 1 | 6 | 1 | 2.78 |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
Savara currently has a consensus price target of $9.13, suggesting a potential upside of 81.77%. Given Savara’s stronger consensus rating and higher possible upside, equities analysts plainly believe Savara is more favorable than Champions Oncology.
Profitability
This table compares Savara and Champions Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Savara | N/A | -87.19% | -66.42% |
| Champions Oncology | -3.94% | -57.31% | -7.51% |
Insider and Institutional Ownership
87.9% of Savara shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 47.0% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Savara has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
